ELVN

19.68

6.60% -1.39

After Hours: 19.68

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $19.68, with a volume of 574.09K. It is down -6.60% in the last 24 hours and down -5.52% over the past month.

Previous Close:

$21.07

Open:

$20.48

24h Volume:

574.09K

Relative Volume:

2.57

Market Cap:

$1.05B

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-10.41

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

-12.38%

1M Performance:

-5.52%

6M Performance:

-22.94%

1Y Performance:

+11.88%

1-Day Range:

$19.48

$21.16

1-Week Range:

$19.48

$22.61

52-Week Range:

$15.96

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	19.68	1.05B	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

07:55 AM

Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock - Investing.com

07:55 AM

Mar 30, 2025

Where are the Opportunities in (ELVN) - news.stocktradersdaily.com

Mar 30, 2025

Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 30, 2025

Mar 26, 2025

Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com South Africa

Mar 26, 2025

Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India

Mar 26, 2025

Mar 25, 2025

Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 25, 2025

Mar 23, 2025

HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World

Mar 23, 2025

Mar 22, 2025

Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 22, 2025

Mar 21, 2025

Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada

Mar 21, 2025

Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India

Mar 21, 2025

Mar 20, 2025

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com

Mar 20, 2025

Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK

Mar 19, 2025

Mar 15, 2025

Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com

Mar 15, 2025

Mar 14, 2025

Enliven grew fourth-quarter R&D spending with trials underway - BizWest

Mar 14, 2025

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value The Markets

Mar 14, 2025

Enliven Therapeutics Reports 2024 Financial Results - TipRanks

Mar 14, 2025

Mar 13, 2025

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune

Mar 13, 2025